Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
48
SVA Quote, Financials, Valuation and Earnings
Last price:
$6.47
Seasonality move
:
13.44%
Day range:
$6.47 - $6.47
52-week range:
$6.25 - $6.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.05x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$464.9M
Revenue:
$448.3M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SVA
Sinovac Biotech
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene
|
-- | -$0.51 | -- | -- | -- |
|
CASI
CASI Pharmaceuticals
|
$4.6M | -- | -- | -- | -- |
|
CPHI
China Pharma Holding
|
-- | -- | -- | -- | -- |
|
LSB
LakeShore Biopharma
|
$21.8M | -$0.08 | -11.69% | -92.36% | -- |
|
ZLAB
Zai Lab
|
$102.2M | -$0.78 | 65.01% | -27.07% | $52.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech
|
$6.47 | -- | $464.9M | -- | $0.00 | 0% | 1.50x |
|
ADAG
Adagene
|
$2.04 | -- | $90.3M | -- | $0.00 | 0% | 4.96x |
|
CASI
CASI Pharmaceuticals
|
$2.65 | -- | $41M | -- | $0.00 | 0% | 1.67x |
|
CPHI
China Pharma Holding
|
$0.17 | -- | $3.4M | -- | $0.00 | 0% | 0.45x |
|
LSB
LakeShore Biopharma
|
$2.96 | -- | $56.5M | -- | $0.00 | 0% | 0.47x |
|
ZLAB
Zai Lab
|
$26.74 | $52.39 | $2.9B | -- | $0.00 | 0% | 7.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SVA
Sinovac Biotech
|
3.46% | 0.000 | 12.91% | 11.22x |
|
ADAG
Adagene
|
-- | -0.344 | -- | -- |
|
CASI
CASI Pharmaceuticals
|
58% | 2.930 | 20.08% | 2.17x |
|
CPHI
China Pharma Holding
|
37.7% | -0.264 | 64.12% | 0.24x |
|
LSB
LakeShore Biopharma
|
37.85% | 4.419 | 40.21% | 0.79x |
|
ZLAB
Zai Lab
|
14.47% | -1.034 | 4.76% | 2.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ADAG
Adagene
|
-- | -- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals
|
$4M | -$8.1M | -82.29% | -137% | -103.75% | -- |
|
CPHI
China Pharma Holding
|
-$519.7K | -$1.1M | -41.21% | -66.27% | -98.51% | -$37.7K |
|
LSB
LakeShore Biopharma
|
-- | -- | -15.63% | -7.94% | -- | -- |
|
ZLAB
Zai Lab
|
$65.3M | -$64M | -33.5% | -35.53% | -40.02% | -$56.7M |
Sinovac Biotech vs. Competitors
-
Which has Higher Returns SVA or ADAG?
Adagene has a net margin of -- compared to Sinovac Biotech's net margin of --. Sinovac Biotech's return on equity of -1.05% beat Adagene's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech-- -- $11.8B ADAGAdagene-- -- -- -
What do Analysts Say About SVA or ADAG?
Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene has an analysts' consensus of -- which suggests that it could grow by 293.51%. Given that Adagene has higher upside potential than Sinovac Biotech, analysts believe Adagene is more attractive than Sinovac Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech0 0 0 ADAGAdagene0 0 0 -
Is SVA or ADAG More Risky?
Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SVA or ADAG?
Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. Adagene pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ADAG?
Sinovac Biotech quarterly revenues are --, which are smaller than Adagene quarterly revenues of --. Sinovac Biotech's net income of -- is lower than Adagene's net income of --. Notably, Sinovac Biotech's price-to-earnings ratio is -- while Adagene's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 4.96x for Adagene. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech1.50x -- -- -- ADAGAdagene4.96x -- -- --
-
Which has Higher Returns SVA or CASI?
CASI Pharmaceuticals has a net margin of -- compared to Sinovac Biotech's net margin of -107.73%. Sinovac Biotech's return on equity of -1.05% beat CASI Pharmaceuticals's return on equity of -137%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech-- -- $11.8B CASICASI Pharmaceuticals51.91% -$0.55 $33M -
What do Analysts Say About SVA or CASI?
Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 126.42%. Given that CASI Pharmaceuticals has higher upside potential than Sinovac Biotech, analysts believe CASI Pharmaceuticals is more attractive than Sinovac Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech0 0 0 CASICASI Pharmaceuticals0 0 0 -
Is SVA or CASI More Risky?
Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.577%.
-
Which is a Better Dividend Stock SVA or CASI?
Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or CASI?
Sinovac Biotech quarterly revenues are --, which are smaller than CASI Pharmaceuticals quarterly revenues of $7.8M. Sinovac Biotech's net income of -- is lower than CASI Pharmaceuticals's net income of -$8.4M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 1.67x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech1.50x -- -- -- CASICASI Pharmaceuticals1.67x -- $7.8M -$8.4M
-
Which has Higher Returns SVA or CPHI?
China Pharma Holding has a net margin of -- compared to Sinovac Biotech's net margin of -101.61%. Sinovac Biotech's return on equity of -1.05% beat China Pharma Holding's return on equity of -66.27%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech-- -- $11.8B CPHIChina Pharma Holding-47.23% -$0.06 $10.5M -
What do Analysts Say About SVA or CPHI?
Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech has higher upside potential than China Pharma Holding, analysts believe Sinovac Biotech is more attractive than China Pharma Holding.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech0 0 0 CPHIChina Pharma Holding0 0 0 -
Is SVA or CPHI More Risky?
Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.874%.
-
Which is a Better Dividend Stock SVA or CPHI?
Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or CPHI?
Sinovac Biotech quarterly revenues are --, which are smaller than China Pharma Holding quarterly revenues of $1.1M. Sinovac Biotech's net income of -- is lower than China Pharma Holding's net income of -$1.1M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 0.45x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech1.50x -- -- -- CPHIChina Pharma Holding0.45x -- $1.1M -$1.1M
-
Which has Higher Returns SVA or LSB?
LakeShore Biopharma has a net margin of -- compared to Sinovac Biotech's net margin of --. Sinovac Biotech's return on equity of -1.05% beat LakeShore Biopharma's return on equity of -7.94%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech-- -- $11.8B LSBLakeShore Biopharma-- -- $138.3M -
What do Analysts Say About SVA or LSB?
Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand LakeShore Biopharma has an analysts' consensus of -- which suggests that it could grow by 964.57%. Given that LakeShore Biopharma has higher upside potential than Sinovac Biotech, analysts believe LakeShore Biopharma is more attractive than Sinovac Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech0 0 0 LSBLakeShore Biopharma0 0 0 -
Is SVA or LSB More Risky?
Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LakeShore Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SVA or LSB?
Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LakeShore Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. LakeShore Biopharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or LSB?
Sinovac Biotech quarterly revenues are --, which are smaller than LakeShore Biopharma quarterly revenues of --. Sinovac Biotech's net income of -- is lower than LakeShore Biopharma's net income of --. Notably, Sinovac Biotech's price-to-earnings ratio is -- while LakeShore Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 0.47x for LakeShore Biopharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech1.50x -- -- -- LSBLakeShore Biopharma0.47x -- -- --
-
Which has Higher Returns SVA or ZLAB?
Zai Lab has a net margin of -- compared to Sinovac Biotech's net margin of -40.75%. Sinovac Biotech's return on equity of -1.05% beat Zai Lab's return on equity of -35.53%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech-- -- $11.8B ZLABZai Lab63.9% -$0.40 $780.7M -
What do Analysts Say About SVA or ZLAB?
Sinovac Biotech has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 95.93%. Given that Zai Lab has higher upside potential than Sinovac Biotech, analysts believe Zai Lab is more attractive than Sinovac Biotech.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech0 0 0 ZLABZai Lab8 0 0 -
Is SVA or ZLAB More Risky?
Sinovac Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.
-
Which is a Better Dividend Stock SVA or ZLAB?
Sinovac Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech pays -328.35% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ZLAB?
Sinovac Biotech quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $102.3M. Sinovac Biotech's net income of -- is lower than Zai Lab's net income of -$41.7M. Notably, Sinovac Biotech's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech is 1.50x versus 7.33x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech1.50x -- -- -- ZLABZai Lab7.33x -- $102.3M -$41.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
